A pproximately 3% of the general population harbors an unruptured intracranial aneurysm (UIA). 1 UIA is not a benign condition because aneurysm rupture can lead to subarachnoid hemorrhage (SAH). Mortality risks are between 30% and 45% for aneurysmal SAH and up to 20% of survivors will be permanently disabled. 2 Thus, interventional procedures are often used to obliterate an UIA with the goal of eliminating rupture risk and SAH. However, the annual risk of rupture for most UIAs tends to be low (between 0.5% and 1%) [3] [4] [5] and between 50% and 80% of aneurysms do not rupture over a person's lifetime. 6 Decisions about UIA management must, therefore, balance the risks of procedures used to obliterate the UIA against the natural history risk.
Patient age is a key decision-making factor because older patients face higher procedural risks 4, 7 and a shorter period of natural history risk. Accordingly, the overall benefit of interventions for UIAs is likely to vary by age. However, 20% to 25% of patients with UIAs who undergo clipping or coiling are ≥65 years, 7, 8 and little is known about population-level trends in the use and outcomes of these procedures in this patient group. The objective of this study was to evaluate trends in the use of clipping and coiling for UIAs, changes in outcomes after clipping and coiling of UIAs, and changes in the occurrence of SAH among Medicare beneficiaries over time.
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Study Population
The study population consisted of 2 cohorts: one to describe trends in utilization of clipping and coiling (utilization cohort, 2000-2010) and one to describe changes in patient characteristics and outcomes over time (outcomes cohort, 2001-2010 .79) only once in a given year but could contribute again in later years if they underwent another procedure. The outcomes cohort consisted of patients aged ≥66 years of age that were continuously enrolled in Medicare for ≥1 year (baseline period) before being admitted electively for the clipping or coiling of an UIA. Patients undergoing >1 procedure were categorized according to their first procedure. If clipping and coiling occurred on the same day, patients were assumed to have undergone a conversion from coiling to clipping and were categorized as having undergone coiling.
Outcomes
The outcomes of interest included mortality (in-hospital, 30-day), 30-day hospital readmissions, length of stay, discharge disposition (dead, home without health care, transferred to acute care, transferred to long-term care), and a composite in-hospital end point consisting of potential complications of procedural treatment including stroke, hydrocephalus, ventriculostomy, ventricular shunt, tracheotomy, prolonged mechanical ventilation, and postoperative neurological, cardiovascular, or surgical site complications (Table I in the online-only Data Supplement). We followed patients from the procedure date until the earliest of the following events: the outcomes, death, loss of Medicare eligibility, or the end of the study period (December 31, 2010).
Study Variables
We obtained patient date of birth, sex, and race (which we categorized as white or nonwhite). Using algorithms validated in the Medicare population whenever possible, we identified past-year hospitalizations of ischemic stroke, hemorrhagic stroke, myocardial infarction, coronary artery bypass graft, atrial fibrillation, congestive heart failure, ischemic heart disease, diabetes mellitus, hypertension, hyperlipidemia, chronic kidney disease, chronic obstructive pulmonary disorder, and cancer (Table II in the online-only Data Supplement) . To assess overall comorbidity burden, we calculated the Elixhauser comorbidity score. 10 Performing hospitals were described in terms of ownership (government, investor owned, and not-for-profit), metropolitan location (yes/no), and teaching affiliation (yes/no). To calculate hospital procedural volume, we counted the number of procedures performed among Medicare beneficiaries in the year preceding the index date in a given center.
Analysis
From the utilization cohort, we calculated the yearly rate of UIA clipping and coiling procedures per 100 000 Medicare beneficiaries overall and stratified by age group (65-74 versus ≥75 years). We assessed changes in patient characteristics and in performing centers over time by aggregating patients in the outcomes cohort into 3 time blocks (2001-2003, 2004-2007, and 2008-2010) and report percentages for categorical variables and means and SDs or medians and interquartile ranges for continuous variables. These time blocks were selected based on the fact that patient characteristics did not change appreciably from year to year and on the assumption that any changes in outcomes would likely be driven by changes in rates of uptake or procedural technology. Due to the ≥1 year continuous eligibility requirement for the outcomes cohort, patient characteristics and outcomes are reported for clipping and coiling of UIAs from 2001 onward. We report unadjusted risks and 95% confidence intervals for outcomes, derived from Kaplan-Meier estimators by procedure across time blocks. We tested for trends over the time blocks using Jonckheere-Terpstra tests for in-hospital outcomes, Spearman rank order correlation test for medians, t test from linear regression for means, and type III Wald χ 2 test for peri-procedural outcomes. We used a validated SAH algorithm 11 to estimate SAH rates per 100 000 beneficiaries over the study period, age-and sex-standardized to the 2010 Medicare population. We used SAS 9.4 (The SAS Institute, Cary, NC) for all analyses. The institutional review board of Weill Cornell Medical College approved the study. Rates of UIA clipping and coiling tended to increase more among Medicare patients aged 65 to 74 years than among patients aged ≥75 years ( Figure 2 ). Rates of clipping per 100 000 Medicare beneficiaries increased from 1.9 to 2.8 between 2000 and 2010 for patients aged 65 to 74 years and remained relatively unchanged for patients aged ≥75 years (0.4 in 2000 versus 0.5 in 2010). The increase in coiling rates per 100 000 beneficiaries from 2000 to 2010 was more pronounced among patients aged 65 to 74 years (0.4 versus 6.0) than among those aged ≥75 years (0.2 versus 2.4). Overall, the proportion of patients with UIAs undergoing coiling increased from 42.2% to 66.0% in the 66 to 74 age group and increased from 59.3% to 82.7% in the group aged ≥75 years (Table III in the online-only Data Supplement). Characteristics of patients undergoing clipping or coiling did not differ substantially across age groups. 
Results

Trends in UIA Clipping and Coiling
Changes in Characteristics of Patients With UIAs Undergoing Clipping and Treating Hospitals
Patient demographics did not vary substantially from 2001 to 2010; mean age ranged from 70.6 to 71.0 years, between 75.1% and 77.1% were women, and the proportion of white patients ranged from 88.5% to 92.0% (Table 1) . There was little change in comorbidity prevalence and in the mean Elixhauser Comorbidity score. Characteristics of centers performing UIA clipping changed during the study period; the proportion of not-for-profit institutions increased from 72.2% over 2001 to 2003 to 77.8% over 2008 to 2010, the proportion of metropolitan centers performing the procedure increased from 74.5% to 80.0% and the mean Medicare pastyear hospital clipping volume increased from 10.8 to 14.9 procedures.
Changes in Characteristics of Patients With UIAs Undergoing Coiling and Treating Hospitals
Similar to clipping, demographics of patients undergoing coiling did not change during the study period; mean age ranged from 72.4 to 72.5 years, between 78.0% and 80.7% were women, and the proportion of white patients ranged from 88.1% to 90.8% (Table 1) (Table IV in the online-only Data Supplement).
Trends in outcomes of clipping and coiling were consistent when the analysis was repeated using 1-or 2-year time blocks.
Trends in SAH 2000 to 2010
Age-and sex-adjusted rates of SAH remained relatively stable at ≈20 per 100 000 until 2007 (Figure 3) . Starting in 2008, the rate of SAH increased to ≈25 per 100 000 Medicare beneficiaries.
Discussion
Between 2000 and 2010, the rate of Medicare beneficiaries undergoing procedural treatment for UIA increased several fold. This increase was driven mainly by the rate of patients undergoing coiling, which increased almost 15-fold between 2000 and 2010. Although characteristics of patients with UIA being treated with clipping or coiling did not change substantially, mean past-year Medicare hospital procedural volume increased steadily for clipping and more than doubled for coiling during the study period. Over time, outcomes for patients undergoing both clipping and coiling tended to get better, but we did not observe a decrease in SAH rates over the same time period.
Our findings support and advance results of other studies reporting increasing use of UIA clipping and coiling. [12] [13] [14] One of the factors contributing to the increase in the rate of UIAs being managed through clipping and coiling may be related to increased detection of UIAs. Consistent with this hypothesis is the fact that imaging services reimbursed by Medicare Part B more than doubled from 2000 and 2006 15 and that, among fee-for-service Medicare beneficiaries, the use of noninvasive imaging techniques to assess the arterial vasculature of the head such as computer tomographic angiography and magnetic resonance angiography increased by 827% and 39%, respectively, between 2002 and 2007. 16 Although routine screening for UIAs is not recommended in the general population, 17 the majority of UIAs are discovered incidentally. 3, 18 Our findings suggest that increased use of imaging techniques in the Medicare population reported previously may be translating into more UIAs being incidentally discovered and subsequently treated.
Our study also suggests that coiling has now become the first-line procedural therapy for patients with UIA if they are eligible for both the procedures. This can be at least partially explained by the fact that coiling is considered less physiologically stressful and safer than clipping, as implied by numerous observational studies, which have shown that clipping is associated with a higher risk of adverse outcomes. 12, 13, [19] [20] [21] The risk of adverse outcomes tended to decrease for both clipping and coiling over time and is probably due to advancements in endovascular techniques, 12 general improvements in postprocedural care, and increasing past-year clipping, and coiling volumes. 22, 23 We tended to observe the lowest procedural harms for patients undergoing coiling in 2008 to 2010, when peri-procedural mortality was 1.5%, nonfatal in-hospital complications risks were 13.8%, 30-day hospital readmissions were 11.0%, and discharge to long-term care was 15.0%. Nevertheless, reductions in peri-procedural morbidity and mortality do not necessarily justify increased preventative UIA treatment. The risk of these events must be weighed against the annual rate of UIA rupture, which generally ranges between 0.5% and 1.0%, 3-5 but may be much higher depending on size, site, SAH history, aneurysmal symptoms, and smoking status. [3] [4] [5] 24 In addition, the value of procedural treatment must be weighed against life expectancy, which will be lower among Medicare patients than among the general population because of differences in age and comorbidity burden.
Little robust evidence exists that routine UIA treatment results in a net clinical benefit. In this context, the trend we observed in the rate of SAH during the study period is concerning. The primary purpose of preventative UIA clipping and coiling is to reduce the risk of aneurysmal SAH occurrence. However, in spite of the dramatic increase in the rates of procedures, particularly coiling, performed on Medicare beneficiaries with UIAs, the overall rate of SAH among Medicare beneficiaries did not decrease. This is the opposite of what would be expected if procedural treatment of UIAs was preventing aneurysm ruptures that would have occurred without treatment. Therefore, it is reasonable to suspect that for some patients in this age group, the value of clipping or coiling their UIAs is either modest or nonexistent, particularly in light of procedural complications and the effect of procedure-associated morbidity and hospitalizations on quality of life.
The results of this study must be interpreted in the context of certain limitations. We were not able to investigate longterm outcome risks such as aneurysm recurrence and we did not have postprocedural information on the modified Rankin Scale Score or other measures of dependency. Although discharge to long-term care is likely a good proxy for functional disability, the expected benefits of preventive clipping and coiling need to be weighed against other factors affecting survival and quality of life that were not measured in this study. We observed nondecreasing SAH rates but could not determine whether it was because of UIA treatment complications (which appeared to be decreasing), aneurysm recurrence, limited life expectancy, insufficient study follow-up time, or another mechanism. Finally, we did not have information on size, stability, and location of UIAs and could not determine if and how the selection of treated UIAs changed over time nor whether outcomes for UIAs with certain characteristics improved more so than others. †Discharged against medical advice are considered missing/unknown (<1% of cases). 
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There are several implications of our study. First, we think the main question for preventative UIA treatment may be not whether coiling is better than clipping but rather what level of risk, if any, is justified. In this study, we did not observe a decrease in SAH rates as clipping and coiling rates increased. Because the risk of rupture is low, it may be that some patients do not live long enough to benefit from the primary purpose of the procedure: SAH prevention. Second, we found that patients between the ages of 65 to 74 years tended to have greater increases in the rates of clipping and coiling during the study period, which probably reflects the selection of patients most likely to benefit from preventative UIA treatment. Further studies should further aid providers in identifying Medicare beneficiaries who are most likely to benefit from preventative UIA treatment, given the possibility for significant competing risks, peri-procedural complication risks, and low rates of rupture. Finally, randomized clinical trials and real-world observational studies comparing the different treatment modalities for UIA, including conservative management, are also needed to determine the optimal management strategy for UIA, particularly in older adults.
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